Clinical and regulatory intelligence for Biliary Tract Cancer with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 3
Catalysts: 0
Assets: 3

Relevant assets

binimetinib →

Sintilimab →

Zolbetuximab →

Relevant companies

Astellas Pharma Inc →

Recent signals(3)

ClinicalJuly 25, 2026

Zolbetuximab in Combination with Chemotherapy for Advanced Biliary Tract Cancers

A clinical trial is investigating zolbetuximab combined with either CAPOX or mFOLFOX6 in patients with advanced biliary tract cancers.

ClinicalJune 26, 2026

Phase II Trial of Binimetinib with mFOLFOX6 in Advanced Biliary Tract Cancers

A phase II trial is evaluating the efficacy of binimetinib combined with mFOLFOX6 chemotherapy in patients with advanced biliary tract cancers.

ClinicalJune 18, 2026

Sintilimab and Ipilimumab Show Promise in First-line Therapy for Advanced Biliary Tract Cancers

The combination of sintilimab and ipilimumab is being evaluated as a first-line therapy for unresectable and metastatic biliary tract cancers, addressing unmet needs in current treatment regimens.

Upcoming catalysts

No catalysts indexed for this entity yet.

Therapeutic areas

Biliary Tract Cancer →

Oncology →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.